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Intensive chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab is the standard first line treatment in younger and physically fit patients with chronic lymphocytic leukemia (CLL). 1 Older and physically less fit patients with CLL have been underrepresented in past clinical trials and, therefore, no standard of care has been established for these so far. Treating such patients with the alkylating drug chlorambucil (CLB) remains a valuable option, 2,3 but complete remissions are generally rare and disease progression mostly occurs o2 years after the start of therapy. The addition of CD20-antibodies to CLB has been proposed to improve alkylator-based therapy of CLL. Two recent phase 2 trials explored chemoimmunotherapy with CLB and rituximab and reported higher complete response rates compared with those historically observed with CLB monotherapy. 4, 5 Outcome of treatments combining CLB with novel CD20-antibodies (for example, obinutuzumab, ofatumumab, veltuzumab) has not yet been published. It, therefore, has remained unclear whether such regimens are safe and feasible in patients with CLL, particularly if those patients are of advanced age and afflicted with comorbidity.
Obinutuzumab (GA101) is a glycoengineered, humanized type II CD20-antibody that has demonstrated superior activity compared with type I antibodies in preclinical studies. [6] [7] [8] In phase 1/2 trials, monotherapy with GA101 in patients with relapsed or refractory CLL has been shown to be safe and with promising activity. 9, 10 Therefore, a multicenter international 3-arm protocol (CLL11/ BO21004) was initiated comparing GA101 plus CLB (G-CLB) with rituximab plus CLB (R-CLB) or CLB alone in previously untreated CLL patients with increased comorbidity. Before the opening of randomization, six subjects with CLL received G-CLB treatment within a safety run-in phase to investigate whether this treatment combination is feasible in a patient population characterized by an increased burden of comorbidity. 11 Only previously untreated patients requiring treatment were included. Comorbidity was assessed by the Cumulative Illness Rating Scale and renal function by calculation of the creatinine clearance at baseline using the Cockcroft-Gault formula. 12, 13 For enrollment, patients were required to have a Cumulative Illness Rating Scale total score46 and/or a creatinine clearance of 30-69 ml/min. All patients were planned to receive six cycles of G-CLB, each of 4 weeks in duration. GA101 was administered intravenously at a 1000 mg flat dose on day 1, day 8 and day 15 of cycle 1 and on day 1 of cycles 2-6. CLB was given orally at 0.5 mg/kg body weight on day 1 and day 15 of each cycle (equivalent to the median dose used in a previous trial on elderly patients with CLL). 3 This analysis is based on data collected by 11 November 2011. Treatment toxicity was reported according to the National Cancer Institute Common Toxicity Criteria (CTC version 4.0, Bethesda, MD, USA). Occurrence of (i) three episodes of febrile neutropenia or infections requiring antibiotic therapy or (ii) one treatment-related death during the first cycle were defined as stopping criteria for the trial. Treatment response and status of remission during follow-up were assessed according to International Workshop on CLL guidelines. 11 Minimal residual disease was measured as reported previously.
14 The protocol was approved by the institutional review boards of participating sites and performed in accordance with the Declaration of Helsinki. The CLL11 (BO21004) trial is registered at www.clinicaltrials.gov (NCT01010061).
Baseline characteristics of the six patients and individual treatment outcomes are summarized in Table 1 . All subjects were older than 70 years and had multiple comorbidities and/or impaired renal function, thus representing a small sample of highly vulnerable patients who normally would have been excluded from clinical trials in CLL. Infusion-related reactions (IRR) occurred in five patients, but were generally mild and except for one patient limited to the first infusion. The frequency of IRR may be viewed as surprisingly high for a fully humanized antibody. Yet, a possible explanation is that the rapid clearing of the peripheral blood from lymphocytes ( Figure 1 ) lead to cytokine release and associated symptoms. This hypothesis is supported by the comparatively low incidence of IRR observed in previous lymphoma studies with GA101. 9, 15 Whether the risk of IRR in CLL is properly balanced with potential long-term benefits emerging from an immediate hematological response to G-CLB treatment is important to be evaluated during the randomized phase of the trial. A total of 10 episodes of afebrile grade 3-4 neutropenia were reported in five of the six patients; four of those patients received granulocyte colony stimulating factor (G-CSF) (eight doses in total). However, neither did these transient neutropenias translate into grade 3-4 infections, nor did they cause fever or require antibiotic therapy. Furthermore, there were no grade 3-4 neutropenias or infections during a 6-months period after end of treatment.
All subjects completed treatment, but two had significant dosing delays, one due to a mechanical ileus unrelated to therapy requiring surgical intervention and another patient presenting with a psychotic disorder. Both patients also had prolonged neutropenia. All six patients responded to treatment and kept their remission by the time of data analysis. None of the patients had died until that timepoint. Figure 1 . Peripheral blood lymphocyte counts during and after chemoimmunotherapy with GA101 plus chlorambucil.
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In conclusion, chemoimmunotherapy with GA101 and CLB is feasible in CLL patients of advanced age and with high burden of comorbidity. The treatment combination has promising activity in this group of patients that so far has been severely neglected by clinical research. IRR and neutropenia were identified as potential risks of the G-CLB regimen. As none of the stopping criteria defined for the safety run-in phase of the trial was met, the CLL11 (BO21004) trial was opened for randomization in April 2010. Although previously tested in an upfront window by the BerlinFrankfurt-Munster group, the safety and efficacy of rituximab in combination with multiagent chemotherapy regimens in children and adolescents with advanced mature B-cell non-Hodgkin lymphoma (B-NHL) is unknown. 1 The trial, COG ANHL01P1, was open to all Children's Oncology Group (COG) centers in the United States, Canada, Australia and New Zealand. The protocol was approved at each institutional review board. Parents or patients signed informed consent in accordance with the Declaration of Helsinki. The COG-
CONFLICT OF INTEREST

